Millennium Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-47,600
Closed -$3.24M 7764
2022
Q3
$3.24M Buy
+47,600
New +$2.63M ﹤0.01% 3308
2021
Q3
Sell
-40,000
Closed -$1.4M 7492
2021
Q2
$1.4M Buy
40,000
+30,000
+300% +$1.17M ﹤0.01% 4336
2021
Q1
$408K Buy
+10,000
New +$460K ﹤0.01% 4992
2020
Q4
Sell
-7,500
Closed -$414 5735
2020
Q3
$414 Sell
7,500
-10,000
-57% -$636K ﹤0.01% 3666
2020
Q2
$1.1M Buy
+17,500
New +$1.2M ﹤0.01% 2932
2020
Q1
Sell
-40,000
Closed -$3.18M 4728
2019
Q4
$3.18M Sell
40,000
-60,000
-60% -$3.56M ﹤0.01% 2286
2019
Q3
$4.85M Sell
100,000
-7,100
-7% -$370K 0.01% 1831
2019
Q2
$5.63M Buy
+107,100
New +$6.15M 0.01% 1678
2018
Q4
Sell
-392,300
Closed -$14.9M 4333
2018
Q3
$14.9M Buy
392,300
+177,300
+82% +$7.85M 0.02% 1030
2018
Q2
$9.72M Buy
215,000
+172,000
+400% +$7.83M 0.01% 1332
2018
Q1
$2.08M Buy
+43,000
New +$2.4M ﹤0.01% 2287
2016
Q3
Sell
-50,000
Closed -$830K 3718
2016
Q2
$830K Buy
+50,000
New +$1.01M ﹤0.01% 2250

Other funds holding GBT

Millennium Management's GBT Position: Q4 2022 in Review

Millennium Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 543,632 shares — an estimated $37M sold.

Millennium Management first reported a position in GBT in Q3 2015 and held it in 24 quarters. The position peaked at $37M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Millennium Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Millennium Management sold 543,632 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $37M.
  • Millennium Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 24 quarters.
  • Millennium Management's Global Blood Therapeutics, Inc. position peaked at $37M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.